CODOX-M/IVAC-R versus DA-EPOCH-R in double/triple-hit large B cell lymphoma in patients ≤ 60 years.

• DOI: 10.1200/jco.2024.42.16_suppl.7067
• Publication Date: 2024-06-10T18:38:11Z
• Authors: Suheil Albert Ata...; Matthew J. Rees; Thomas E. Witzig; Thomas Matthew Ha...; Ellen D McPhail; Javier Munoz; Madiha Iqbal; Grzegorz S. Nowak...
• Keywords: Epoch (astronomy); Log-rank test

7067 Background: High intensity induction with regimens such asDA-EPOCH-R, CODOX-M/IVAC-R and HyperCVAD are often used for young patients DHL/THL despite no overall survival (OS) benefit compared to R-CHOP. Reports on the application of subject selection bias as only fit can tolerate it. We aimed investigate outcomes difference between DA-EPOCH-R in ≤ 60 years diagnosed via FISH. Methods: Retrospective review from Mayo Clinic July15 th 2010-October19th 2023 treated or at age up years. Event free (EFS) was defined time diagnosis progression, relapse, next line treatment death any cause. Results: 113 were included; (N=49) (N=64). Patient disease characteristics table. 80% (N=39) achieved CR end (EOT) PET CT 58% (N=37) DA-EPOCH-R. associated superior EFS univariate (HR=0.54, 95%CI=0.31-0.97) multivariable analysis adjusted age, BCL2 vs BCL6 translocation receipt consolidation ASCT (aHR=0.53, 95%CI=0.29-0.95), however, there significant influence OS (aHR=0.97, 95%CI=0.50-1.91). At a median follow-up 5.3 3.3 CODOX-M-IVAC DA-R-EPOCH group respectively; having 1, 2 5 68.3%, 64.1 61.5% respectively 52.4%, 48.9% 39.5% (p=0.035). 33%(16/49) had R/R (No EOT relapsed) 10.3 months 33.7 DA EPOCH-R (54%, 35/64). Number who able receive salvage ASCT, CAR T Allo-SCT 5, 17 4 6 3 group. None died regimen toxicity both groups. 19% underwent after initial (11 each group); noticed however increased regardless best being (P=0.0072). Conclusions: Our study showed that received benefit. spare receiving more subsequent therapies. Patients have following poor outcomes. [Table: see text]